Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Lung Cancer. 2022 09; 171:103-114.